Replimune Group (NASDAQ:REPL) is at the forefront of developing oncolytic immuno-gene therapies aimed at treating cancer. With a focus on innovation, they harness cutting-edge genetic engineering techniques to create therapies designed to directly attack tumors while also stimulating a systemic anti-tumor response. Replimune is dedicated to pushing the boundaries of medicine to offer new hope to patients battling cancer. Their portfolio showcases a variety of projects targeting different aspects of oncology, demonstrating their commitment to broadening options for cancer treatment. The company's goals include advancing their therapies through clinical trials, achieving regulatory milestones, and eventually bringing these novel treatments to market to improve outcomes for patients worldwide.